181 related articles for article (PubMed ID: 38192129)
1. Understanding the Role of Galectin-1 in Heart Failure: A Comprehensive Narrative Review.
Sotoudeheian MJ; Mirahmadi SM; Pirhayati M; Azarbad R; Nematollahi S; Taghizadeh M; Pazoki-Toroudi H
Curr Cardiol Rev; 2024 Jan; 20(1):. PubMed ID: 38192129
[TBL] [Abstract][Full Text] [Related]
2. Galectin-1 attenuates cardiomyocyte hypertrophy through splice-variant specific modulation of Ca
Fan J; Fan W; Lei J; Zhou Y; Xu H; Kapoor I; Zhu G; Wang J
Biochim Biophys Acta Mol Basis Dis; 2019 Jan; 1865(1):218-229. PubMed ID: 30463690
[TBL] [Abstract][Full Text] [Related]
3. CT-1 (Cardiotrophin-1)-Gal-3 (Galectin-3) Axis in Cardiac Fibrosis and Inflammation.
Martínez-Martínez E; Brugnolaro C; Ibarrola J; Ravassa S; Buonafine M; López B; Fernández-Celis A; Querejeta R; Santamaria E; Fernández-Irigoyen J; Rábago G; Moreno MU; Jaisser F; Díez J; González A; López-Andrés N
Hypertension; 2019 Mar; 73(3):602-611. PubMed ID: 30612490
[TBL] [Abstract][Full Text] [Related]
4. The diagnostic and prognostic value of galectin-3 in patients at risk for heart failure with preserved ejection fraction: results from the DIAST-CHF study.
Trippel TD; Mende M; Düngen HD; Hashemi D; Petutschnigg J; Nolte K; Herrmann-Lingen C; Binder L; Hasenfuss G; Pieske B; Wachter R; Edelmann F
ESC Heart Fail; 2021 Apr; 8(2):829-841. PubMed ID: 33566456
[TBL] [Abstract][Full Text] [Related]
5. Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure.
Gopal DM; Kommineni M; Ayalon N; Koelbl C; Ayalon R; Biolo A; Dember LM; Downing J; Siwik DA; Liang CS; Colucci WS
J Am Heart Assoc; 2012 Oct; 1(5):e000760. PubMed ID: 23316284
[TBL] [Abstract][Full Text] [Related]
6. The Role of Galectin-3 in Heart Failure-The Diagnostic, Prognostic and Therapeutic Potential-Where Do We Stand?
Zaborska B; Sikora-Frąc M; Smarż K; Pilichowska-Paszkiet E; Budaj A; Sitkiewicz D; Sygitowicz G
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685918
[TBL] [Abstract][Full Text] [Related]
7. The Diagnostic and Prognostic Value of Plasma Galectin 3 in HFrEF Related to the Etiology of Heart Failure.
Lu Q; Zhang RC; Chen SP; Li T; Wang Y; Xue YB; Liu J; Han X; Su YD; Bai L; Du XJ; Ma AQ
Front Cardiovasc Med; 2021; 8():748875. PubMed ID: 35004876
[No Abstract] [Full Text] [Related]
8. N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin.
Liu YH; D'Ambrosio M; Liao TD; Peng H; Rhaleb NE; Sharma U; André S; Gabius HJ; Carretero OA
Am J Physiol Heart Circ Physiol; 2009 Feb; 296(2):H404-12. PubMed ID: 19098114
[TBL] [Abstract][Full Text] [Related]
9. Impact of moderately reduced renal function on the diagnostic and prognostic value of galectin-3 in patients with exertional dyspnea.
Karolko B; Serafin A; Przewłocka-Kosmala M
Adv Clin Exp Med; 2022 Aug; 31(8):873-879. PubMed ID: 35467088
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of galectin-3 post-infarction impedes progressive fibrosis by regulating inflammatory profibrotic cascades.
Wang X; Gaur M; Mounzih K; Rodriguez HJ; Qiu H; Chen M; Yan L; Cooper BA; Narayan S; Derakhshandeh R; Rao P; Han DD; Nabavizadeh P; Springer ML; John CM
Cardiovasc Res; 2023 Nov; 119(15):2536-2549. PubMed ID: 37602717
[TBL] [Abstract][Full Text] [Related]
11. The potential prognostic utility of salivary galectin-3 concentrations in heart failure.
Zhang X; Karunathilaka N; Senanayake S; Subramaniam VN; Chan W; Kostner K; Fraser J; Atherton JJ; Punyadeera C
Clin Res Cardiol; 2020 Jun; 109(6):685-692. PubMed ID: 31598750
[TBL] [Abstract][Full Text] [Related]
12. Galectin-3: A Cardiomyocyte Antiapoptotic Mediator at 24-Hour Post Myocardial Infarction.
Al-Salam S; Hashmi S; Jagadeesh GS; Tariq S
Cell Physiol Biochem; 2020 Apr; 54(2):287-302. PubMed ID: 32246616
[TBL] [Abstract][Full Text] [Related]
13. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3.
Bayes-Genis A; de Antonio M; Vila J; Peñafiel J; Galán A; Barallat J; Zamora E; Urrutia A; Lupón J
J Am Coll Cardiol; 2014 Jan; 63(2):158-66. PubMed ID: 24076531
[TBL] [Abstract][Full Text] [Related]
14. Galectin-3, Metabolic Risk, and Incident Heart Failure: The ARIC Study.
Echouffo-Tcheugui JB; Zhang S; Florido R; Pankow JS; Michos ED; Goldberg RB; Nambi V; Gerstenblith G; Post WS; Blumenthal RS; Ballantyne CM; Coresh J; Selvin E; Ndumele CE
J Am Heart Assoc; 2024 Mar; 13(6):e031607. PubMed ID: 38471823
[TBL] [Abstract][Full Text] [Related]
15. Unraveling the role of galectin-3 in cardiac pathology and physiology.
Seropian IM; Cassaglia P; Miksztowicz V; González GE
Front Physiol; 2023; 14():1304735. PubMed ID: 38170009
[TBL] [Abstract][Full Text] [Related]
16. Association of Galectin-3 and Soluble ST2, and Their Changes, with Echocardiographic Parameters and Development of Heart Failure after ST-Segment Elevation Myocardial Infarction.
Tymińska A; Kapłon-Cieślicka A; Ozierański K; Budnik M; Wancerz A; Sypień P; Peller M; Balsam P; Opolski G; Filipiak KJ
Dis Markers; 2019; 2019():9529053. PubMed ID: 31687050
[TBL] [Abstract][Full Text] [Related]
17. Regulation of Blood Pressure by Targeting Ca
Hu Z; Li G; Wang JW; Chong SY; Yu D; Wang X; Soon JL; Liang MC; Wong YP; Huang N; Colecraft HM; Liao P; Soong TW
Circulation; 2018 Oct; 138(14):1431-1445. PubMed ID: 29650545
[TBL] [Abstract][Full Text] [Related]
18. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial.
Lopez-Andrès N; Rossignol P; Iraqi W; Fay R; Nuée J; Ghio S; Cleland JG; Zannad F; Lacolley P
Eur J Heart Fail; 2012 Jan; 14(1):74-81. PubMed ID: 22089058
[TBL] [Abstract][Full Text] [Related]
19. Comparison the prognostic value of galectin-3 and serum markers of cardiac extracellular matrix turnover in patients with chronic systolic heart failure.
Chang YY; Chen A; Wu XM; Hsu TP; Liu LY; Chen YH; Wu YW; Lin HJ; Hsu RB; Lee CM; Wang SS; Lo MT; Chen MF; Lin YH
Int J Med Sci; 2014; 11(11):1098-106. PubMed ID: 25170292
[TBL] [Abstract][Full Text] [Related]
20. Regulated expression of galectin-1 during T-cell activation involves Lck and Fyn kinases and signaling through MEK1/ERK, p38 MAP kinase and p70S6 kinase.
Fuertes MB; Molinero LL; Toscano MA; Ilarregui JM; Rubinstein N; Fainboim L; Zwirner NW; Rabinovich GA
Mol Cell Biochem; 2004 Dec; 267(1-2):177-85. PubMed ID: 15663199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
